EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN
Publication
, Conference
Keir, ST; Friedman, HS; Bigner, DD
Published in: NEURO-ONCOLOGY
October 1, 2012
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2012
Volume
14
Start / End Page
29 / 29
Location
Washington, DC
Publisher
OXFORD UNIV PRESS INC
Conference Name
17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Keir, S. T., Friedman, H. S., & Bigner, D. D. (2012). EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN. In NEURO-ONCOLOGY (Vol. 14, pp. 29–29). Washington, DC: OXFORD UNIV PRESS INC.
Keir, Stephen T., Henry S. Friedman, and Darell D. Bigner. “EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN.” In NEURO-ONCOLOGY, 14:29–29. OXFORD UNIV PRESS INC, 2012.
Keir ST, Friedman HS, Bigner DD. EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 29–29.
Keir, Stephen T., et al. “EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN.” NEURO-ONCOLOGY, vol. 14, OXFORD UNIV PRESS INC, 2012, pp. 29–29.
Keir ST, Friedman HS, Bigner DD. EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 29–29.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2012
Volume
14
Start / End Page
29 / 29
Location
Washington, DC
Publisher
OXFORD UNIV PRESS INC
Conference Name
17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences